“When buprenorphine was approved for office-based treatment of opioid addiction in the U.S, doctors worried about possible liver toxicity. We’d seen case reports of acute liver necrosis (death of liver tissue) in patients with Hepatitis C who injected buprenorphine illicitly. So was this damage due to the drug itself, from intravenous use of the sublingual product, or from buprenorphine interaction with Hepatitis C? Until we had more information, experts recommended checking liver function tests before starting buprenorphine and periodically during treatment to monitor for liver damage.
Fortunately, further studies show no liver damage in patients prescribed buprenorphine.”
Source: Dr. Jana Burson – November 23, 2014